Lataa...
Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy
Recently, immunotherapeutic drugs, including PD-1 inhibitors (nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, avelumab), and CTLA4 inhibitors (ipiliumumab), have emerged as important additions to the armamentarium against certain malignancies and have been incorporated into therapeutic pr...
Tallennettuna:
| Julkaisussa: | Case Rep Oncol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
S. Karger AG
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5126613/ https://ncbi.nlm.nih.gov/pubmed/27920704 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000452296 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|